Prof. Jens D. Lundgren: Co-PI for the START study, the Chair of the Steering Committee for the D:A:D study, the founder and current member of the steering committee for the EuroSIDA study*, the founder of the EACS non-infectious co-morbidity guidelines panel.
Department of Infectious Diseases, Director of CHIP (Centre of Excellence for Health, Immunity and Infections), Rigshospitalet, University of Copenhagen, Denmark
1. Remaining challenges in European continent to contain the HIV epidemic? 0:11
2. What are the limiting factors in the cascade of care? 0:58
3. What needs to be done to improve standards of care? 2:30
4. Why it is so important to treat HIV+ persons for the community at large? 4:29
5. What are the main outcomes of large EuroSIDA study? 5:05
* ”The EuroSIDA study is a prospective observational cohort study of more than 23000 patients followed in 100 hospitals in 35 European countries. The main objective is to follow the long-term clinical prognosis for the general population of HIV-infected patients and to assess the impact of antiretroviral drugs on the long-term prognosis for these patients…”